晚期非小细胞肺癌患者未治疗比例上升:一项倾向性匹配分析
该研究利用美国国家癌症数据库1998至2012年数据,分析晚期非小细胞肺癌的治疗趋势及未治疗与生存的关系。结果显示21%的患者(190,539例)未接受治疗,IIIA期和IV期未治疗比例分别上升0.21%和0.4%(p=0.003和p<0.0001)。倾向性匹配分析中,接受放化疗或化疗的患者总生存均优于未治疗者。
要点
- 1998至2012年,21%的原发性非小细胞肺癌患者(190,539例)未接受治疗。
- IIIA期和IV期未治疗患者比例分别上升0.21%和0.4%(p=0.003和p<0.0001)。
- 匹配分析显示IIIA期放化疗者中位OS 16.5个月 vs 未治疗者6.1个月(p<0.0001)。
核心结论
- IIIA期和IV期非小细胞肺癌中未治疗患者比例正在增加。
- 晚期患者接受治疗的生存结局优于未治疗,且独立于选择偏倚。
- 在决定放弃治疗前应仔细评估治疗的获益与风险。
研究设计与样本
- 基于美国国家癌症数据库1998至2012年原发性非小细胞肺癌患者的分析。
- 采用线性回归计算治疗利用趋势,Kaplan-Meier和Cox回归模型确定接受治疗的预测因素。
- 采用倾向性匹配比较治疗与未治疗亚组的生存。
主要发现
- 21%的患者(190,539例)未接受治疗。
- IIIA期和IV期未治疗患者比例分别增加0.21%和0.4%(p=0.003和p<0.0001)。
- 无论分期,未治疗患者总生存显著缩短(p<0.0001)。
- 6144对IIIA期倾向匹配患者中,放化疗组中位OS 16.5个月 vs 未治疗组6.1个月(p<0.0001)。
- 19,046对IV期倾向匹配患者中,化疗组中位OS 9.3个月 vs 未治疗组2.0个月(p<0.0001)。
关键数值与推荐
- 21%的患者(190,539例)未接受治疗。
- IIIA期未治疗比例上升0.21%(p=0.003),IV期上升0.4%(p<0.0001)。
- IIIA期匹配分析:放化疗组中位OS 16.5个月 vs 未治疗组6.1个月(p<0.0001)。
- IV期匹配分析:化疗组中位OS 9.3个月 vs 未治疗组2.0个月(p<0.0001)。
临床怎么用
- 原文结论指出在决定放弃治疗前应仔细评估治疗的获益与风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Variation in treatment and survival outcomes for NSCLC is high among patients with stage III or IV disease, but patients with untreated NSCLC have not been critically analyzed to evaluate for improvable outcomes. We evaluated treatment trends and their association with oncologic outcomes for NSCLC, hypothesizing that there are a substantial number of untreated patients who are similar to patients who undergo treatment. METHODS: Linear regression was used to calculate trends in utilization of treatment. Kaplan-Meier and Cox regression modeling were used to determine predictors of receiving treatment. Propensity matching was used to compare survival among subsets of treated versus untreated patients. RESULTS: Patients with primary NSCLC were identified from the National Cancer Data base from 1998 to 2012, and 21% of patients (190,539) received no treatment. For stage IIIA and IV, the proportion of untreated patients increased over the study period by 0.21% and 0.4%, respectively (p = 0.003 and p < 0.0001). Regardless of stage, untreated patients had significantly shorter overall survival (OS) (p < 0.0001). Propensity-matched analyses of 6144 stage IIIA patient pairs treated with chemoradiation versus no treatment confirmed shorter OS for untreated patients (median 16.5 versus 6.1 months, p < 0.0001). For 19,046 stage IV patient pairs treated with chemotherapy versus no treatment, similar results were obtained (median OS 9.3 versus 2.0 months, p < 0.0001). CONCLUSIONS: The proportion of untreated patients with stage IIIA and IV disease is increasing. Survival outcomes among patients with advanced-stage disease are superior with treatment, independent of selection bias. The benefits and risks of treatment should be carefully assessed before choosing to forego treatment.
引用
- David EA, Daly ME, Li CS, et al. Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis. J Thorac Oncol. 2017. PMID: 28109804. doi:10.1016/j.jtho.2016.11.2221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。